A Study Evaluating the Effect of Esomeprazole on SYN-004 Degradation of Ceftriaxone In Adults With an Ileostomy
A Phase 1b/2a, Multi-Center, Open-Label, 2-Period, Fixed-Sequence Study Evaluating the Effect of Esomeprazole on SYN-004 Degradation of Ceftriaxone In Healthy Adult Subjects With a Functioning Ileostomy
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Phase 2
- Phase 1
Contacts and Locations
Study Locations
-
-
-
Montreal, Canada
- Synthetic Biologics Investigative Site
-
-
Alberta
-
Edmonton, Alberta, Canada
- Synthetic Biologics Investigative Site
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- The subject has a functioning ileostomy that has been in place for ≥ 3 months.
- The subject is male or female between the ages of 18 and 80 years, inclusive.
- Other than a functioning ileostomy, the subject is free from clinically significant illnesses or disease.
Exclusion Criteria:
- Subjects who have active hepatic, small intestine, or biliary tract disease.
- Subjects who have active ulcerative colitis, Crohn's disease, other inflammatory bowel disease.
- Subjects with known malignancy requiring treatment < 6 months prior to study screening.
- Subjects who have, in the opinion of the investigator, significant concurrent medical illness.
- Subjects who are currently taking concomitant medications which may interfere with study evaluation.
- Subjects who have received an investigational drug within 30 days or within a time period consistent with a washout period of 5 half-lives, whichever is longer, of the first dose of ceftriaxone.
- Subjects with a known history of allergy to any cephalosporin, penicillin or any β-lactam antibiotic.
- Subjects who have known active malabsorption syndromes(s) that, in the judgment of the investigator, could compromise the objectives of the study.
- Subjects who have used any oral, intramuscular, or IV anti-microbial medication during the last 3 week
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: 150 mg SYN-004
There will be 2 in-house treatment periods: in Treatment Period 1, subjects will receive 2 oral doses of 150 mg SYN-004 (two 75 mg capsules) and 1g ceftriaxone, and in Treatment Period 2, subjects will receive 2 oral doses of 150mg SYN-004 (two 75 mg capsules) and 1g ceftriaxone in the presence of steady-state esomeprazole; Treatment Periods 1 and 2 will be separated by a 5- to 7-day run-in phase, during which subjects will self-administer 40 mg of esomeprazole once daily (QD) in the morning, at home.
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Ceftriaxone Concentration in Intestinal Chyme Period 1
Time Frame: 0-8.5 hours
|
Ceftriaxone concentration in the presence of SYN-004 and the absence of esomeprazole.
|
0-8.5 hours
|
|
Ribaxamase Concentration in Intestinal Chyme Period 1
Time Frame: 0-8.5 hours
|
Concentrations of ribaximase (SYN-004) in intestinal chyme
|
0-8.5 hours
|
|
Ceftriaxone Concentration in Intestinal Chyme Period 2
Time Frame: 0-8.5 hours
|
Ceftriaxone concentration in the presence of SYN-004 and the absence of esomeprazole.
|
0-8.5 hours
|
|
Ribaxamase Concentration in Intestinal Chyme Period 2
Time Frame: 0-8.5 hours
|
Concentrations of ribaximase (SYN-004) in intestinal chyme
|
0-8.5 hours
|
Collaborators and Investigators
Sponsor
Sponsor
Publications and helpful links
Study record dates
Study Major Dates
Study Start
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Estimate)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- SB-1-004-004
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.